Drug Profile
Monoclonal antibody Dal B02
Latest Information Update: 08 Sep 1998
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lymphoid leukaemia
Most Recent Events
- 08 Sep 1998 Profile reviewed
- 08 Sep 1998 No-Development-Reported for Lymphoid leukaemia in Canada (Unknown route)
- 06 Sep 1996 Preclinical development for Lymphoid leukaemia in Canada (Unknown route)